• linkedin
  • Increase Font
  • Sharebar

    FDA clears new drug application for topical psoriasis treatment

    The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.

    The lotion, if approved, would be the first of its kind to combine tazarotene and halobetasol propionate in a single formulation for psoriasis in adult patients, according to the company, which is a division of Valeant.

    In initial trials, the most common adverse events were application site pain (2.6 percent) and contact dermatitis (7.4 percent).

    Sarah Thuerk
    Sarah Thuerk is associate editor of Healthcare Traveler magazine.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow